Glioblastoma is the most common type of brain tumor that affects adults and, unfortunately, still remains incurable. In a new study, researchers have demonstrated that a specific mitochondrial protein plays an important role in glioblastoma, and can therefore be used as a potential target to reduce tumors.

Several Cancer Center at Illinois (CCIL) and IGB members are joining forces with scientists from the Mayo Clinic and Georgetown University on an expansive project targeting improved treatment for glioblastoma (GBM), the most aggressive form of brain cancer. The team, led by Brendan Harley (RBTE leader/EIRH), professor of chemical and biomolecular engineering, recently received a $3M grant from the National Cancer Institute (NCI) for their research which will unite the cell biology, bioengineering, and chemistry behind cancer drug development.